Skip to main content
Videoconference and publication of the 2020-2021 Half-Year Results, on December 9, 2020
December 2, 2020
First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date
November 12, 2020
Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board
November 9, 2020
MedinCell initiates the first clinical trial of its Covid-19 prevention program
September 29, 2020
MedinCell releases the results of its September 10, 2020 ordinary annual and extraordinary general meeting
September 11, 2020
Participation terms in the MedinCell Combined General Meeting and availability of preparatory documents
July 31, 2020
MedinCell announces the availability of its 2019/2020 Universal Registration Document including the Annual Financial Report
July 29, 2020
MedinCell announces the great success of its capital increase and raises 15.6 M€
June 16, 2020
MedinCell launches a capital increase of a minimum of 11 M€
June 15, 2020
MedinCell successfully renegotiates the drawdown conditions of the last tranche of the EIB loan and secures an additional €5m of non-dilutive funding
June 10, 2020
